Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labor and Welfare, or MHLW, in Japan has granted marketing and manufacturing authorization for Dupixent for the treatment of chronic spontaneous urticaria, or CSU, in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the first country to approve Dupixent for CSU, emphasizing the value of Dupixent as a novel treatment option to manage this disease in patients with unmet needs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
- Regeneron exec LaRosa sells 1,000 common shares
- Regeneron Announces Investor Conference Presentations
- Regeneron Pharmaceuticals Is Worried About This – Should You Be Worried Too?
- Regeneron price target raised to $1,135 from $1,045 at Truist
